)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sysmex
Sysmex (6869) investor relations material
Sysmex Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary11 Nov, 2026
Executive summary
H1 FY2027 net sales rose 17.3% YoY to ¥272.8B and operating profit increased 1.4% to ¥33.4B; attributable profit fell 5.7% to ¥17.9B.
Growth in Japan, the Americas and EMEA offset weaker China results; FY2027 forecasts were revised upward.
Financial highlights
H1 net sales were ¥272,822M, operating profit ¥33,428M, profit before tax ¥29,137M and attributable profit ¥17,933M.
Gross profit was ¥140,434M; SG&A was ¥85,476M and R&D expense ¥14,226M.
Impairment losses totaled ¥5,769M, related to goodwill and other assets from the BioMajesty business combination.
Operating cash flow was ¥67,094M, up ¥29,032M YoY; free cash flow was ¥34.0B, up ¥22.6B.
Outlook and guidance
Revised FY2027 forecast: net sales ¥550.0B, operating profit ¥68.5B and attributable profit ¥40.0B.
Versus the August forecast, sales increased ¥5.0B, operating profit ¥8.5B and attributable profit ¥3.0B; the H2 operating profit forecast is unchanged.
FY2027 targets include ROE of 8.0%, ROIC of 8.5%, operating cash flow of ¥99.0B and free cash flow of ¥38.0B.
Planned capex is ¥48.0B; the annual dividend forecast is ¥40 per share, including ¥20 at year-end.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sysmex
- Record FY2024 results underpin FY2025 growth guidance.6869
Q4 2024 - Targets ¥600B sales, 12%+ ROE by FY2029, driven by diagnostics, AI, and digital transformation.6869Investor update
- Strong sales and profit growth, raised outlook and dividends, but China remains a risk.6869Q1 2027
- Global diagnostics leader drives growth through innovation, emerging markets, and new businesses.6869Investor presentation
- Profit and sales fell on China weakness, but global growth and higher dividends are forecast.6869Q4 2026
- Profits fell on China and Japan weakness, but EMEA and Americas segments showed strong growth.6869Q3 2026
- Profits fell on lower sales in Japan and China, but global expansion and new business support growth.6869Q2 2026
- Profits and sales fell sharply, but full-year guidance and dividend plans remain intact.6869Q1 2026
- Record Q1 sales and profit growth driven by global reagent demand and new product launches.6869Q1 2025
Next Sysmex earnings date
Q3 202711 Feb, 2027
Sysmex
Next Sysmex earnings date
Q3 202711 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sysmex Corporation is a Japanese company in the healthcare sector, primarily engaged in the development, manufacture, and sales of diagnostic instruments, reagents, and health management support software. Founded in 1968, as TOA Medical Electronics, it later adopted the Sysmex brand in 1978, initially focusing on haematology analysers before expanding its product range. Sysmex's solutions encompass haematology, haemostasis, and urinalysis analyzers, with research and development centers in Japan, France, New Zealand, Germany, and the US. The company is headquartered in Kobe, Japan, and its shares are listed on the Tokyo Stock Exchange.